27 January 2023

The advantages to using fluorescence vs radioactivity in receptors kinetic and binding assays.

WHY IS IMPORTANT TO CONSIDER MULTIPLE ASSAY TYPES FOR TARGETS CHARACTERIZATION? Usually, in the identification of new drug-like molecules for a target of interest it is […]
26 January 2023

Transform your idea in to molecules

Custom synthesis service for fluorescent ligands Celtarys provides custom chemical development services, specifically for the identification of a broad range of robust and complex fluorescent ligands […]
20 December 2022

Fluorescent ligands used to unravel the insights of GPCRs as Cancer Drivers

Malignant cells often hijack the normal physiological functions of GPCRs to survive, proliferate autonomously, evade the immune system, increase their blood supply, invade their surrounding tissues […]
19 December 2022

Celtarys Research has signed a strategic research cooperation agreement with the European platform EU-OPENSCREEN

We are glad to announce that Celtarys Research has reached a strategic research cooperation agreement with the European platform EU-OPENSCREEN (https://www.eu-openscreen.eu ), a not-for-profit European Research Infrastructure […]
18 November 2022

Discover Our New Fluorescent Ligands For Adrenergic Receptor

Our portfolio of #GPCR#fluorescent ligands is growingWe have just added to our catalogue two more fluorescent ligands for the α1-Adrenergic receptor, CELT-130 and CELT-133. α1-Adrenergic receptors play a vital role in the regulation of […]
9 November 2022

Celtarys Research, sponsor of the XIV Meeting of the Spanish Drug Discovery Network

The XIV meeting of the Spanish Drug Discovery Network (SDDN) will take place in Granada, Spain, on November 24 and 25, 2022. This international conference has […]
7 November 2022

New fluorescent tools to evaluate the therapeutic potential of phytocannabinoids

Cannabinoid receptors, CB1 and CB2 are two extensively studied targets of the GPCR family for the treatment of numerous conditions, including inflammatory diseases, autoimmune disorders, pain, […]
26 October 2022

Video webinar – Celtarys Colorectal Cancer & GPCR Fluorescent ligands

G-protein coupled receptors (GPCRs) have been targeted mainly in a wide range of diseases. Still, few therapies have been directed against GPCRs in the field of cancer, […]
20 September 2022

Fluorescent ligands: A New Method to Label your GPCRs

To date, it has been reported that about 800 GPCRs are encoded by the human genome. Some of them have known ligands available which led to the […]